Venetoclax联合低甲基化药物治疗复发/难治性急性髓性白血病:来自单一中心的病例系列

Q2 Medicine Journal of Buon Pub Date : 2021-09-01

Sema Secilmis, Mehmet Sinan Dal, Merih Kizil Cakar, Alparslan Merdin, Nuran Ahu Baysal, Fevzi Altuntas

{"title":"Venetoclax联合低甲基化药物治疗复发/难治性急性髓性白血病:来自单一中心的病例系列","authors":"Sema Secilmis, Mehmet Sinan Dal, Merih Kizil Cakar, Alparslan Merdin, Nuran Ahu Baysal, Fevzi Altuntas","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).Results: More than half of the patients could go on with venetoclax for only a few months.Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"2026-2032"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.\",\"authors\":\"Sema Secilmis, Mehmet Sinan Dal, Merih Kizil Cakar, Alparslan Merdin, Nuran Ahu Baysal, Fevzi Altuntas\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).Results: More than half of the patients could go on with venetoclax for only a few months.Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.\",\"PeriodicalId\":50248,\"journal\":{\"name\":\"Journal of Buon\",\"volume\":\" \",\"pages\":\"2026-2032\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Buon\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的:Venetoclax (VEN)是一种抗凋亡蛋白b细胞白血病/淋巴瘤-2 (BCL-2)的口服选择性抑制剂。方法:我们报告了7例复发/难治性(R/R)急性髓性白血病(AML)患者使用venetoclax和低甲基化药物(HMA)治疗。结果:半数以上患者仅能坚持使用维妥乐几个月。结论:venetoclax联合HMA治疗R/R AML应作为一种替代的抢救选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.

Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).

Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).

Results: More than half of the patients could go on with venetoclax for only a few months.

Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.